BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31235801)

  • 1. Contemporary national trends in prostate cancer risk profile at diagnosis.
    Fletcher SA; von Landenberg N; Cole AP; Gild P; Choueiri TK; Lipsitz SR; Trinh QD; Kibel AS
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):81-87. PubMed ID: 31235801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
    Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
    Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
    Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
    Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very-high-risk localized prostate cancer: definition and outcomes.
    Sundi D; Wang VM; Pierorazio PM; Han M; Bivalacqua TJ; Ball MW; Antonarakis ES; Partin AW; Schaeffer EM; Ross AE
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):57-63. PubMed ID: 24189998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
    Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
    BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade.
    Beatrici E; Filipas DK; Stone BV; Labban M; Qian Z; Lipsitz SR; Lughezzani G; Buffi NM; Cole AP; Trinh QD
    Urol Oncol; 2023 Dec; 41(12):483.e11-483.e19. PubMed ID: 37852818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grade Migration of Prostate Cancer in the United States During the Last Decade.
    Borregales LD; DeMeo G; Gu X; Cheng E; Dudley V; Schaeffer EM; Nagar H; Carlsson S; Vickers A; Hu JC
    J Natl Cancer Inst; 2022 Jul; 114(7):1012-1019. PubMed ID: 35348709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).
    Cooperberg MR; Lubeck DP; Mehta SS; Carroll PR;
    J Urol; 2003 Dec; 170(6 Pt 2):S21-5; discussion S26-7. PubMed ID: 14610406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening among elderly men in Brazil: should we diagnose or not?
    Mori RR; Faria EF; Mauad EC; Rodrigues AA; Dos Reis RB
    Int Braz J Urol; 2020; 46(1):34-41. PubMed ID: 31851456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
    Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
    BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system.
    Reese AC; Pierorazio PM; Han M; Partin AW
    Urology; 2012 Nov; 80(5):1075-9. PubMed ID: 22995570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
    Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
    World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
    Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.